Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Brown sold 1,700 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $142,868.00. Following the transaction, the executive vice president directly owned 99,885 shares in the company, valued at $8,394,335.40. The trade was a 1.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DexCom stock opened at $87.93 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock’s fifty day moving average price is $83.82 and its 200-day moving average price is $73.17. The firm has a market cap of $33.18 billion, a P/E ratio of 34.76, a P/E/G ratio of 1.46 and a beta of 1.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 earnings per share. On average, equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Plato Investment Management Ltd purchased a new position in shares of DexCom in the second quarter worth about $782,000. Aurora Investment Counsel acquired a new position in DexCom in the 2nd quarter worth approximately $2,340,000. E Fund Management Co. Ltd. acquired a new position in DexCom in the 2nd quarter worth approximately $1,273,000. Silvant Capital Management LLC purchased a new position in DexCom during the 2nd quarter worth approximately $5,359,000. Finally, Performance Wealth Partners LLC purchased a new position in DexCom during the 2nd quarter worth approximately $1,740,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of analyst reports. Robert W. Baird set a $105.00 target price on DexCom in a report on Friday, July 31st. Mizuho lifted their price target on DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Citigroup restated a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.